These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 24304429)

  • 1. A retrospective analysis of the risk factors for allergic reactions induced by the administration of oxaliplatin.
    Yamauchi H; Goto T; Takayoshi K; Sagara K; Uoi M; Kawanabe C; Matsunaga M; Miyoshi T; Uchino K; Misumi N; Nishino T
    Eur J Cancer Care (Engl); 2015; 24(1):111-6. PubMed ID: 24304429
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A single-arm Phase II validation study of preventing oxaliplatin-induced hypersensitivity reactions by dexamethasone: the AVOID trial.
    Yoshida Y; Hirata K; Matsuoka H; Iwamoto S; Kotaka M; Fujita H; Aisu N; Hoshino S; Kosaka T; Maeda K; Kiyomi F; Yamashita Y
    Drug Des Devel Ther; 2015; 9():6067-73. PubMed ID: 26648694
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oxaliplatin-induced allergic reaction in patients with colorectal cancer in Japan.
    Shibata Y; Ariyama H; Baba E; Takii Y; Esaki T; Mitsugi K; Tsuchiya T; Kusaba H; Akashi K; Nakano S
    Int J Clin Oncol; 2009 Oct; 14(5):397-401. PubMed ID: 19856046
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-dose dexamethasone plus antihistamine prevents colorectal cancer patients treated with modified FOLFOX6 from hypersensitivity reactions induced by oxaliplatin.
    Kidera Y; Satoh T; Ueda S; Okamoto W; Okamoto I; Fumita S; Yonesaka K; Hayashi H; Makimura C; Okamoto K; Kiyota H; Tsurutani J; Miyazaki M; Yoshinaga M; Fujiwara K; Yamazoe Y; Moriyama K; Tsubaki M; Chiba Y; Nishida S; Nakagawa K
    Int J Clin Oncol; 2011 Jun; 16(3):244-9. PubMed ID: 21243395
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Analysis of Hypersensitivity Reactions to Oxaliplatin Among Colorectal Cancer Patients.
    Shen Y; Li C; Liu W; Mao W; Qian H; Wang H; Xu Q
    Oncol Res; 2018 Jun; 26(5):801-807. PubMed ID: 29295722
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypersensitivity Reactions to Oxaliplatin: Identifying the Risk Factors and Judging the Efficacy of a Desensitization Protocol.
    Okayama T; Ishikawa T; Sugatani K; Yoshida N; Kokura S; Matsuda K; Tsukamoto S; Ihara N; Kuriu Y; Nakanishi M; Nakamura T; Kamada K; Katada K; Uchiyama K; Takagi T; Handa O; Konishi H; Yagi N; Naito Y; Otsuji E; Hosoi H; Miki T; Itoh Y
    Clin Ther; 2015 Jun; 37(6):1259-69. PubMed ID: 25862137
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of allergic reactions to oxaliplatin in colorectal cancer patients.
    Suenaga M; Mizunuma N; Shinozaki E; Matsusaka S; Chin K; Muto T; Konishi F; Hatake K
    J Support Oncol; 2008; 6(8):373-8. PubMed ID: 19149322
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characteristics and risk factors of oxaliplatin-related hypersensitivity reactions.
    Shao YY; Hu FC; Liang JT; Chiu WT; Cheng AL; Yang CH
    J Formos Med Assoc; 2010 May; 109(5):362-8. PubMed ID: 20497869
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [A retrospective survey on allergic reactions by oxaliplatin].
    Honda S; Yoshimura M; Ohno K; Yamamoto E; Kitada N; Hashida T; Imagawa F
    Gan To Kagaku Ryoho; 2010 Nov; 37(11):2101-4. PubMed ID: 21084807
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypersensitivity to oxaliplatin: an investigation of incidence and risk factors, and literature review.
    Kim BH; Bradley T; Tai J; Budman DR
    Oncology; 2009; 76(4):231-8. PubMed ID: 19246947
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypersensitivity reactions to oxaliplatin: a retrospective study and the development of a desensitization protocol.
    Syrigou EI; Karapanagiotou EM; Alamara CV; Boura PG; Saif MW; Syrigos KN
    Clin Colorectal Cancer; 2009 Apr; 8(2):106-9. PubMed ID: 19739272
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypersensitivity reactions to oxaliplatin in two asian patients.
    Ng CV
    Ann Pharmacother; 2005 Jun; 39(6):1114-8. PubMed ID: 15886290
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypersensitivity reactions to oxaliplatin: experience in a single institute.
    Siu SW; Chan RT; Au GK
    Ann Oncol; 2006 Feb; 17(2):259-61. PubMed ID: 16282245
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical features of hypersensitivity reactions to oxaliplatin: a 10-year experience.
    Polyzos A; Tsavaris N; Gogas H; Souglakos J; Vambakas L; Vardakas N; Polyzos K; Tsigris C; Mantas D; Papachristodoulou A; Nikiteas N; Karavokyros JG; Felekouras E; Griniatsos J; Giannopoulos A; Kouraklis G
    Oncology; 2009; 76(1):36-41. PubMed ID: 19033714
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Successful rechallenge for oxaliplatin hypersensitivity reactions in patients with metastatic colorectal cancer.
    Yanai T; Iwasa S; Hashimoto H; Kato K; Hamaguchi T; Yamada Y; Shimada Y; Yamamoto H
    Anticancer Res; 2012 Dec; 32(12):5521-6. PubMed ID: 23225461
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypersensitivity reactions to oxaliplatin: clinical features and risk factors in Koreans.
    Kim MY; Kang SY; Lee SY; Yang MS; Kim MH; Song WJ; Kim SH; Kim YJ; Lee KW; Cho SH; Min KU; Lee JS; Kim JH; Chang YS
    Asian Pac J Cancer Prev; 2012; 13(4):1209-15. PubMed ID: 22799307
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Allergic-type reactions to oxaliplatin: retrospective analysis of 42 patients.
    Maindrault-Goebel F; André T; Tournigand C; Louvet C; Perez-Staub N; Zeghib N; De Gramont A
    Eur J Cancer; 2005 Oct; 41(15):2262-7. PubMed ID: 16154353
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of local reactions to oxaliplatin infusions by peripheral versus central venous administration.
    To YY; Sutcliffe KJ; Hoen HM; Swaney RA; Nicholls JD; Crocenzi TS
    J Oncol Pharm Pract; 2016 Apr; 22(2):256-60. PubMed ID: 25762052
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical outcomes of reintroducing oxaliplatin to patients with colorectal cancer after mild hypersensitivity reactions.
    Park SJ; Lee KY; Park WS; Min SY
    Oncology; 2013; 85(6):323-7. PubMed ID: 24247529
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bioequivalence of Branded and Generic Oxaliplatin: From Preclinical Assessment to Clinical Incidence of Hypersensitivity Reactions.
    Tampellini M; Benedetto S; Rubatto E; Baratelli C; DI Scipio F; Pirro E; Brizzi MP; Sonetto C; DI Maio M; Berta GN; Scagliotti GV
    Anticancer Res; 2016 Oct; 36(10):5163-5170. PubMed ID: 27798876
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.